GlassScriptPhysician profile
Suzanne Dundon
NPI 1699902528
$7,219.48
in general payments reported to CMS, 2019-2025
30 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $86.24 · 2021: $166 · 2022: $917 · 2023: $1,234 · 2024: $2,044 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,371 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,370.61 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.38 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $854.18 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $671.63 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $615.61 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Genzyme Corporation | $534.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $427.14 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $368.91 | 2023-2025 | Tremfya, Simponi, Stelara |
| Mayne Pharma Commercial LLC | $351.66 | 2019-2025 | |
| Ucb, INC. | $319.95 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $298.57 | 2024-2025 | |
| Galderma Laboratories, L.P. | $290.97 | 2019-2025 | Aklief, Nemluvio |
| Leo Pharma INC. | $275.69 | 2023-2025 | Adbry, Anzupgo |
| Incyte Corporation | $228.37 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $168.05 | 2023-2025 | Jublia, Arazlo, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $144.55 | 2022-2025 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $108.64 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Botanix Sb INC | $52.86 | 2025 | Sofdra |
| Almirall LLC | $47.56 | 2019-2025 | Klisyri |
| Dermavant Sciences, INC. | $44.56 | 2023-2024 | Vtama |
| Organon LLC | $33.14 | 2025 | Vtama |
| Organogenesis INC. | $22.94 | 2024 | |
| Fidia Pharma USA INC. | $18.40 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.52 | 2024 | Spevigo |
| Krystal Biotech INC | $16.93 | 2025 | Vyjuvek |
| Arcutis Biotherapeutics, INC. | $15.99 | 2024 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $14.47 | 2019 | |
| Sebela Pharmaceuticals INC. | $12.77 | 2019 | |
| Boston Scientific Corporation | $12.36 | 2019 | |
| Merck Sharp & Dohme LLC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Dundon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.